title: Pulmonary arterial hypertension caused by treatment with dasatinib for chronic myeloid leukemia -critical alert-.
abstract: We present a case of pulmonary arterial hypertension (PAH), which is potentially related to treatment with dasatinib (Sprycel(®)). A 61-year-old woman, who had been treated with dasatinib for 27 months for chronic myeloid leukemia (CML), visited our hospital complaining of dyspnea. In right heart catheterization, her mean pulmonary arterial pressure was 35 mmHg. After other possible etiologies to cause PAH were excluded, the patient was diagnosed as a dasatinib-related PAH. As notified by U.S. Food and Drug Administration (FDA) in October 2011, we recommend routine cardiopulmonary evaluation before and during treatment with dasatinib in CML patients in terms of the adverse effects of PAH.
authors.affiliation: Division of Cardiology, Internal Medicine III, Hamamatsu University School of Medicine, Japan.
authors.forename: Makoto
authors.initials: M
authors.lastname: Sano
authors.forename: Masao
authors.initials: M
authors.lastname: Saotome
authors.forename: Tsuyoshi
authors.initials: T
authors.lastname: Urushida
authors.forename: Hideki
authors.initials: H
authors.lastname: Katoh
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Satoh
authors.forename: Kazunori
authors.initials: K
authors.lastname: Ohnishi
authors.forename: Hideharu
authors.initials: H
authors.lastname: Hayashi
mesh_terms: D000069439:Dasatinib; D004452:Echocardiography; D004562:Electrocardiography; D065627:Familial Primary Pulmonary Hypertension; D005260:Female; D006801:Humans; D006976:Hypertension, Pulmonary / Q000139:chemically induced* / Q000175:diagnosis* / Q000188:drug therapy; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy*; D008875:Middle Aged; D010879:Piperazines / Q000627:therapeutic use; D047428:Protein Kinase Inhibitors / Q000009:adverse effects / Q000627:therapeutic use; D011687:Purines / Q000627:therapeutic use; D011743:Pyrimidines / Q000009:adverse effects* / Q000627:therapeutic use*; D000068677:Sildenafil Citrate; D013450:Sulfones / Q000627:therapeutic use; D013844:Thiazoles / Q000009:adverse effects* / Q000627:therapeutic use*; D016896:Treatment Outcome; D014665:Vasodilator Agents / Q000627:therapeutic use; D028761:Withholding Treatment
chemical_list: D010879:Piperazines; D047428:Protein Kinase Inhibitors; D011687:Purines; D011743:Pyrimidines; D013450:Sulfones; D013844:Thiazoles; D014665:Vasodilator Agents; D000068677:Sildenafil Citrate; D000069439:Dasatinib